Tepmetko (Tepotinib)

tepotinib 225 mg tablet, 60 · ORAL · PBS code 13171F

STREAMLINED

What it costs

AU$8942.2 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2022-11-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Initial treatment

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must have a WHO performance status of 2 or less; AND

Patient must have evidence of MET exon 14 skipping alterations in tumour material.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not develop disease progression while receiving PBS-subsidised treatment with this drug for this condition; AND

The treatment must be the sole PBS-subsidised therapy for this condition.

Sponsor: Merck Healthcare Pty Ltd ABN 72 006 900 830

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.